Trump signs off on $8.3 billion coronavirus funding legislation passed by US Congress

6 March 2020

The US House of Representatives and Senate on Wednesday and Thursday passed an $8.3 billion emergency funding package, which dwarfs the $2.5 billion request by the White House, and it was signed off by President Donald Trump on Friday morning.

That speedy action by an otherwise bitterly divided Congress underscored just how seriously the government is taking the threat of COVID-19, according to CNBC.

The president signed the emergency funding bill in the Diplomatic Room of the White House alongside Health and Human Services Secretary Alex Azar Friday morning, rather than at the Centers for Disease Control and Prevention (CDC) as originally planned, because of a suspected coronavirus case at the CDC itself.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK